According to MeiraGTx's latest financial reports the company's current revenue (TTM ) is C$47.51 Million. In 2024 the company made a revenue of C$47.75 Million an increase over the revenue in the year 2023 that were of C$18.59 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2025 (TTM) | C$48.6 M | 1.79% |
2024 | C$47.75 M | 156.86% |
2023 | C$18.59 M | -13.94% |
2022 | C$21.6 M | -55.04% |
2021 | C$48.04 M | 142.12% |
2020 | C$19.84 M | 14.31% |
2019 | C$17.36 M | |
2018 | N/A | |
2017 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
![]() Novocure
NVCR | C$0.85 B | 1,701.64% | Jersey |
![]() Novavax NVAX | C$1.67 B | 3,419.88% | ๐บ๐ธ USA |
![]() Organovo ONVO | C$0.19 M | -99.58% | ๐บ๐ธ USA |
![]() Orchard Therapeutics
ORTX | C$30.06 M | -36.71% | ๐ฌ๐ง UK |